Literature DB >> 6668516

Late relapse of testicular cancer.

H R Terebelo, H G Taylor, A Brown, N Martin, F H Stutz, J Blom, L Geier.   

Abstract

The complete response (CR) rate of disseminated germ-cell tumors with current aggressive chemotherapy and surgical resection of localized residual disease is between 70%-80%. Most patients who relapse do so within the first year of therapy. We have observed seven patients with germ-cell tumors treated with a variety of modalities who relapsed after more than two years in CR (45-87 months). Five patients are alive after salvage therapy with follow-up too short to assess the durability of second remission. There were no features distinguishing late relapse patients from all patients treated with chemotherapy for germ-cell tumors. Follow-up in patients treated for germ-cell tumors with chemotherapy should be extended to five years before curability can be established.

Entities:  

Mesh:

Year:  1983        PMID: 6668516     DOI: 10.1200/JCO.1983.1.9.566

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

2.  Management of the post chemotherapy subcentimeter residual mass: the case for observation.

Authors:  Stephen D W Beck; Richard S Foster
Journal:  World J Urol       Date:  2009-07-15       Impact factor: 4.226

3.  Cost- and risk-benefit considerations in the management of clinical stage I nonseminomatous testicular tumors.

Authors:  J Baniel; B J Roth; R S Foster; J P Donohue
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Late Relapse and Follow-up Protocols in Testicular Germ Cell Tumours: The Edinburgh Cancer Centre Experience and Review of the Literature.

Authors:  Beatrice Detti; Paul A Elliott; Duncan B McLaren; Grahame C W Howard
Journal:  Clin Med Oncol       Date:  2008-01-21

5.  Cervical mature teratoma 17 years after initial treatment of testicular teratocarcinoma: report of a late relapse.

Authors:  Ramesh Omranipour; Mina Alavion
Journal:  World J Surg Oncol       Date:  2007-01-04       Impact factor: 2.754

6.  METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma.

Authors:  Jingchao Wei; Yinghao Yin; Jun Zhou; Hanfei Chen; Jingxuan Peng; Jianfu Yang; Yuxin Tang
Journal:  J Cell Mol Med       Date:  2020-08-28       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.